Amylin’s Emerging Role in Next-Generation Weight-Loss and Metabolic Therapies
Amylin is rapidly emerging as the most competitive next-generation target beyond GLP-1 in the global obesity-drug market. The high-stakes bidding for Metsera underscores growing industry confidence in long-acting amylin analogs such as MET-233i, which offers once-monthly dosing and strong synergy with GLP-1 therapies. Compared with GLP-1 alone, amylin provides advantages in satiety, metabolic regulation, and muscle preservation—strengthening its value in future weight-loss strategies.
Pharma leaders including Novo Nordisk, Eli Lilly, Pfizer, Roche, and AbbVie are accelerating investment in amylin monotherapies and multi-target combinations, supported by promising early clinical results. As the field shifts into the post–GLP-1 era, amylin is positioned to become a core commercial driver of next-generation metabolic therapies.
